Chinese Biopharma I-Mab Files For U.S. IPO [Seeking Alpha]
MorphoSys AG - American Depositary Shares (MOR)
Company Research
Source: Seeking Alpha
Chinese Biopharma I-Mab Files For U.S. IPO Summary I-Mab Biopharma has filed to raise $100 million in a U.S. IPO, although the final figure may differ. The firm is advancing an ambitious pipeline of drug treatment candidates. IMAB is preparing for Phase 3 trials for its lead candidate and has an important collaboration with MorphoSys. Quick Take I-Mab Biopharma ( F-1 registration statement The firm is focused on developing new therapeutics for cancers and autoimmune disorders. IMAB has a large pipeline of treatment candidates but has provided no specifics on its Phase 2 trial efficacy results for its lead candidate, TJ202. I'll provide my final thoughts when we learn more about IPO details from management. Company & nology Shanghai, China-based I-Mab Biopharma was founded in 2016 to discover, develop, and commercialize in China and globally new therapeutics for diseases with high unmet clinical needs, primarily cancer and autoimmune disorders. Management is headed by Director and CEO
Show less
Read more
Impact Snapshot
Event Time:
MOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MOR alerts
High impacting MorphoSys AG - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
MOR
News
- MorphoSys: Hold Rating Until The Novartis Deal Closes [Seeking Alpha]Seeking Alpha
- MorphoSys reports Q1 results [Seeking Alpha]Seeking Alpha
- European Stocks Steady as Philips Soars, Deutsche Bank Drops [BNN Bloomberg (Canada)]BNN Bloomberg
- MorphoSys AG Reports First Quarter 2024 Financial Results [Yahoo! Finance]Yahoo! Finance
- MorphoSys AG Reports First Quarter 2024 Financial ResultsBusiness Wire